Canada: API source, and what it actually costs here
The title is the argument: Canada: API source, and what it actually costs here. Here is the rest of it.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
if a clinic will not name the facility, that is your answer
the label on a compounded vial is a legal document, read it
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
do not assume the concentration matches the branded product
[deleted]
the shortage list is the whole legal hinge and people skip it
the shortage list is the whole legal hinge and people skip it
This is the distinction the whole board runs on. Everything else follows from it.
Who is the prescriber, and are they the same organisation as the pharmacy?
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Asked for potency testing on the finished preparation.
Agreed — and the follow-up question is what the beyond-use date is based on.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
- 1do not assume the concentration matches the branded product8 comments in this branch · started by u/eu_apotheke_a